Pascal Biosciences Inc (NEVI) AI Stock Analysis

• Market Cap: C$2.38M
• Dividend Yield: N/A
• Average Volume (3M): 36.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: 5.31%
• EPS Growth: 41.57%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 40
• Industry: Beverages - Non-Alcoholic
• EPS (TTM): 0.00
• Shares Outstanding: 39,662,727
• 10 Day Avg. Volume: 33,832
• 30 Day Avg. Volume: 36,806
• PEG Ratio: -0.35
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 95.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

The stock's overall score reflects positive developments in corporate events, such as strategic expansions and revenue growth, which are offset by ongoing profitability challenges and a negative valuation score due to losses.

Pascal Biosciences Inc Business Overview & Revenue Model

Company Description

Nevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.

How the Company Makes Money

Pascal Biosciences Inc generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its proprietary technologies and compounds through partnerships and licensing agreements with larger pharmaceutical firms. These collaborations often involve milestone payments, research funding, and royalties on sales of successfully developed products. Additionally, Pascal may receive grants and funding from governmental and non-governmental organizations to support its research and development efforts. The company's revenue model is heavily reliant on successful drug development and strategic partnerships within the biotech and pharmaceutical industry.

Pascal Biosciences Inc Financial Statement Overview

Summary

Pascal Biosciences Inc shows revenue growth and positive operational cash flow, but faces challenges with profitability and historical negative equity. Continued focus on cost management and capital structure optimization is crucial.

Income Statement

Pascal Biosciences Inc has shown a moderate improvement in revenue with a TTM revenue of $1,585,656, representing growth from previous periods. However, the company is still facing challenges in profitability with a negative net income of -$259,009. The gross profit margin stands at 61.8%, which is healthy, but the net profit margin is negative due to high operational expenses relative to revenue. EBITDA has turned positive in the TTM, indicating some operational improvement.

Balance Sheet

The balance sheet shows a relatively stable position with total assets of $2,069,189 and stockholders' equity of $1,291,036. The debt-to-equity ratio is 0.36, indicating a reasonable level of leverage. Equity ratio at 62.4% reflects a solid capital structure. However, the company has a history of negative equity, which poses potential financial risks.

Cash Flow

Cash flow from operations is marginally positive at $14,507, signaling a slight recovery. Free cash flow is also positive at $26,962 in the TTM, showing improvement from previous years. However, the free cash flow to net income ratio is negative due to ongoing net losses, and reliance on financing is evident with a significant negative financing cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.55M	671.54K	0.00	0.00	0.00
Gross Profit	1.08M	392.94K	-8.29K	-16.32K	-12.48K
EBITDA	-48.07K	-266.92K	-468.09K	-1.07M	-1.22M
Net Income	-362.48K	-399.77K	-480.28K	-1.09M	-1.24M
Balance Sheet
Total Assets	2.04M	2.50M	18.82K	155.19K	120.71K
Cash, Cash Equivalents and Short-Term Investments	129.54K	418.52K	8.37K	0.00	0.00
Total Debt	528.30K	683.27K	224.62K	7.76K	16.91K
Total Liabilities	813.50K	1.12M	962.93K	646.48K	473.05K
Stockholders Equity	1.23M	1.38M	-944.11K	-491.30K	-352.34K
Cash Flow
Free Cash Flow	-132.06K	-390.49K	-147.68K	-614.93K	-862.83K
Operating Cash Flow	-120.50K	-385.35K	-147.68K	-614.93K	-862.83K
Investing Cash Flow	-11.56K	-947.71K	8.98K	0.00	0.00
Financing Cash Flow	-167.65K	1.76M	154.84K	624.08K	471.07K

Pascal Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NEVI.

Pascal Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.39B	>-0.01	-63.86%	2.36%	16.15%	0.36%
NEVI	50 Neutral	C$2.38M	―	-16.65%	―	5.31%	41.57%
GENX	―	C$1.78M	―	-661.13%	―	―	―
CBP	―	C$1.69M	―		―	―	―
NLVVF	―	$979.66K	―		―	―	―
RAMM	40 Underperform	C$1.19M	―	-70.13%	―	-10.69%	-53.89%
FLOW	―	C$5.83M	―		―	―	―

Pascal Biosciences Inc Corporate Events

Nevis Brands Sees Revenue Growth Amid New Product Launches

Nevis Brands Inc. reported a slight increase in revenue for Q2 2025, driven by stable performance in its licensed markets and the introduction of its hemp-derived THC product line. Despite stable gross margins, the company faced a net loss due to foreign exchange pressures and elevated audit costs. Nevis continues to expand geographically, with growth in New Jersey and Missouri, and anticipates increased sales from its new hemp-derived THC beverage. The company’s asset-light licensing model supports high margins and adaptability to regulatory changes, positioning it for growth as the cannabis beverage market matures.

Nevis Brands Expands Cannabis Beverage Offerings in Illinois and the Carolinas

Nevis Brands Inc has launched its Major™ 100mg cannabis beverage shots in Illinois, expanding its presence in regulated dispensary markets. The company also announced new distribution agreements for its Happy Apple™ hemp-derived THC beverages in North Carolina and South Carolina, aiming to grow its retail presence in bars and specialty outlets. These strategic expansions are expected to enhance Nevis’s market position and revenue streams in both regulated and traditional retail channels.

Nevis Brands Reports 61% Revenue Growth in Q1 2025

Nevis Brands Inc reported a significant 61% increase in revenue for Q1 2025, reaching $416,355, with a gross profit of $323,722 and net income of $60,430. The company attributes this growth to expanding its presence in New Jersey and Missouri while maintaining strong sales in Washington. Nevis is optimistic about its new hemp-derived THC product, Happy Apple, and plans to enter new markets in Q2 2025, indicating a positive outlook for continued growth and market expansion.